Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma

Oncology Reports

Volumn 18, Issue 1, 2007, Pages 47-51

  Fujita, Kyoko ^a   Sano, Daisuke ^a   Kimura, Machiko ^a   Yamashita, Yukiko ^a   Kawakami, Mariko ^a   Ishiguro, Yukari ^a   Nishimura, Goshi ^a   Matsuda, Hideki ^a   Tsukuda, Mamoru ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiangiogenesis; Bevacizumab; Head and neck squamous cell carcinoma; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; MONOCLONAL ANTIBODY; PACLITAXEL; UNCLASSIFIED DRUG; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; FEMALE; HEAD AND NECK TUMOR; HUMAN; METABOLISM; MICROCIRCULATION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TRANSPLANTATION; VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34548023482     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.1.47     Document Type: Article

References (35)

1. Kerbel RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis 21: 505-515, 2000.
2. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611, 2004.
3. Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997. (Pubitemid 27076453)
4. Borgstrom P, Bourdon MA, Hillan KJ, Sriramarao P and Ferrara N: Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo . Prostate 35: 1-10, 1998. (Pubitemid 28158631)
5. Berse B, Brown LF, Van de Water L, Dvorak HF and Senger DR: Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3: 211-220, 1992. (Pubitemid 23084552)
6. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593-4599, 1997. (Pubitemid 27441066)
7. Kim KJ, Li B, Houck K, Winer J and Ferrara N: The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7: 53-64, 1992.
8. Gridelli C, Rossi A and Maione P: New antiangiogenetic agents and non-small cell lung cancer. Crit Rev Oncol Hematol 60: 76-86, 2006. (Pubitemid 44332963)
9. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004. (Pubitemid 38702844)
10. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E and Sarkar S: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23: 3706-3712, 2005.
11. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184-2191, 2004. (Pubitemid 41095154)
12. Cobleigh MA, Langmuir VK, Sledge GW, et al: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30: 117-124, 2003. (Pubitemid 37433402)
13. Sandler AB, Johnson DH and Herbst RS: Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 10: 4258S-4262S, 2004. (Pubitemid 38812458)
14. Sandler A and Herbst R: Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 12: 4421S-4425S, 2006. (Pubitemid 44197192)
15. Fox WD, Higgins B, Maiese KM, et al: Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 8: 3226-3231, 2002. (Pubitemid 35155035)
16. Eisenhauer EA and Vermorken JB: The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 55: 5-30, 1998. (Pubitemid 28035122)
17. Sweeney CJ, Miller KD, Sissons SE, et al: The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61: 3369-3372, 2001. (Pubitemid 32695027)
18. Belotti D, Vergani V, Drudis T, et al: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843-1849, 1996. (Pubitemid 26384151)
19. Lau DH, Xue L, Young LJ, Burke PA and Cheung AT: Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radio-pharm 14: 31-36, 1999. (Pubitemid 29157732)
20. Forastiere AA, Shank D, Neuberg D, Taylor SGT, DeConti RC and Adams G: Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 82: 2270-2274, 1998. (Pubitemid 28240836)
21. Cortes-Funes H and Aisner J: Paclitaxel in head and neck cancer and other tumor types: chairmen's introduction. Semin Oncol 24 (Suppl 2): 51-57, 1997.
22. Forastiere AA and Urba SG: Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Semin Oncol 22: 24-27, 1995.
23. Cassinelli G, Lanzi C, Supino R, et al: Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer. Clin Cancer Res 8: 2647-2654, 2002. (Pubitemid 34856353)
24. Polizzi D, Pratesi G, Tortoreto M, et al: A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts. Cancer Res 59: 1036-1040, 1999. (Pubitemid 29135963)
25. Gossmann A, Helbich TH, Kuriyama N, et al: Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 15: 233-240, 2002. (Pubitemid 34195118)
26. Parangi S, O'Reilly M, Christofori G, et al: Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 93: 2002-2007, 1996. (Pubitemid 26079871)
27. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T and Jaffe RB: Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161: 1917-1924, 2002. (Pubitemid 35265548)
28. Kuramochi H, Hayashi K, Uchida K, et al: Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res 12: 29-33, 2006. (Pubitemid 43166172)
29. Inoue K, Slaton JW, Davis DW, et al: Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 6: 2635-2643, 2000. (Pubitemid 30482098)
30. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989, 2001.
31. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145-147, 2004. (Pubitemid 38524883)
32. Yang JC: Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 10: 6367S-6370S, 2004.
33. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD and Jain RK: Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 59: 3776-3782, 1999. (Pubitemid 29381886)
34. Klement G, Baruchel S, Rak J, et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: R15-R24, 2000. (Pubitemid 30217701)
35. Jaglowski JR and Stack BC Jr: Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of fusaric acid and paclitaxel or carboplatin. Cancer Lett 243: 58-63, 2006. (Pubitemid 44485326)